Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 08-11-2003, 04:18 AM   #1
Paul C.
Posts: n/a
Mark D. Pegram MD associate professor of medicine and director of the Women's Cancer Program University of California Los Angeles provided an update on herceptin-containing combinations for the treatment of breast cancer at the Second Annual "Future of Breast Cancer: An International Breast Cancer Congress."

Dr. Pegram and his team completed two phase II clinical trials each involving 62 patients to assess the safety and efficacy of a TCH regimen consisting of docetaxel (Taxotere) a platinum salt and trastuzumab (Herceptin) in women with breast cancer. In one trial they used the combination of docetaxel carboplatin and trastuzumab and in the other they used cisplatin instead of carboplatin.

Dr. Pegram's update and insights with respect to TCH regimes appear consistent with the findings summarized in San Antonio Breast Cancer Symposium 2002 Abstract 35.

Abstract 35: Robert et al. conducted a phase III trial examining paclitaxel and trastuzumab versus paclitaxel carboplatin and trastuzumab as first-line therapy for metastatic breast cancer. The overall response rate for the triplet was 52% compared with 32% for the doublet. The median time to progression was also significantly longer for patients who received the triplet (13 versus 7 months). Adverse events were similar in both groups except for greater incidence of myelosuppression with the triplet regimen.

  Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump

All times are GMT -7. The time now is 07:09 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2019, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter